EGF and pancreatic neoplasm: A deleterious cross-talk between EGF and TGFβ pathways, enhanced by SMAD4 mutations, has been described by Deharvengt et al. [46], who studied a series of pancreatic cancer cell lines with a different SMAD4 profile.